These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22305834)

  • 1. Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction: Insights from the TRANSFER-AMI trial.
    Lavi S; Cantor WJ; Casanova A; Tan MK; Yan AT; Džavík V; Fitchett D; Cohen EA; Borgundvaag B; Heffernan M; Ducas J; Goodman SG
    Am Heart J; 2012 Feb; 163(2):176-81.e2. PubMed ID: 22305834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial.
    Gibson CM; Murphy SA; Montalescot G; Morrow DA; Ardissino D; Cohen M; Gulba DC; Kracoff OH; Lewis BS; Roguin N; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2238-46. PubMed ID: 17560287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel.
    Sabatine MS; Morrow DA; Dalby A; Pfisterer M; Duris T; Lopez-Sendon J; Murphy SA; Gao R; Antman EM; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(23):2256-63. PubMed ID: 17560290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trial.
    Morrow DA; Antman EM; Murphy SA; Qin J; Ruda M; Guneri S; Jacob AJ; Budaj A; Braunwald E;
    Am Heart J; 2007 Dec; 154(6):1078-84, 1084.e1. PubMed ID: 18035078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
    Antman EM; Morrow DA; McCabe CH; Murphy SA; Ruda M; Sadowski Z; Budaj A; López-Sendón JL; Guneri S; Jiang F; White HD; Fox KA; Braunwald E;
    N Engl J Med; 2006 Apr; 354(14):1477-88. PubMed ID: 16537665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis.
    Giraldez RR; Nicolau JC; Corbalan R; Gurfinkel EP; Juarez U; Lopez-Sendon J; Parkhomenko A; Molhoek P; Mohanavelu S; Morrow DA; Antman EM
    Eur Heart J; 2007 Jul; 28(13):1566-73. PubMed ID: 17562672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
    White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
    Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of enoxaparin in unselected patients with ST-segment elevation myocardial infarction.
    Zeymer U; Gitt A; Jünger C; Bauer T; Heer T; Koeth O; Wienbergen H; Zahn R; Senges J
    Thromb Haemost; 2008 Jan; 99(1):150-4. PubMed ID: 18217147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
    Montalescot G; Ellis SG; de Belder MA; Janssens L; Katz O; Pluta W; Ecollan P; Tendera M; van Boven AJ; Widimsky P; Andersen HR; Betriu A; Armstrong P; Brodie BR; Herrmann HC; Neumann FJ; Effron MB; Lu J; Barnathan ES; Topol EJ;
    JACC Cardiovasc Interv; 2010 Feb; 3(2):203-12. PubMed ID: 20170878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.
    Scirica BM; Morrow DA; Sadowski Z; Ruda M; Nicolau JC; Giugliano RP; Wiviott SD; Sabatine MS; Shui A; Antman EM; Braunwald E
    Eur Heart J; 2007 Sep; 28(17):2070-6. PubMed ID: 17600039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine early angioplasty after fibrinolysis for acute myocardial infarction.
    Cantor WJ; Fitchett D; Borgundvaag B; Ducas J; Heffernan M; Cohen EA; Morrison LJ; Langer A; Dzavik V; Mehta SR; Lazzam C; Schwartz B; Casanova A; Goodman SG;
    N Engl J Med; 2009 Jun; 360(26):2705-18. PubMed ID: 19553646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST-segment changes: the Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) Electrocardiogram Core Laboratory Substudy.
    Goodman SG; Bozovich GE; Tan M; Dos Santos A; Gurfinkel EP; Cohen M; Langer A;
    Am Heart J; 2006 Apr; 151(4):791-7. PubMed ID: 16569535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes.
    Cohen M; Mahaffey KW; Pieper K; Pollack CV; Antman EM; Hoekstra J; Goodman SG; Langer A; Col JJ; White HD; Califf RM; Ferguson JJ;
    J Am Coll Cardiol; 2006 Oct; 48(7):1346-54. PubMed ID: 17010793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents.
    Li YJ; Rha SW; Chen KY; Jin Z; Wang L; Ramasamy S; Poddar KL; Minami Y; Park JY; Choi CU; Oh DJ; Jeong MH;
    J Cardiol; 2012 Jan; 59(1):22-9. PubMed ID: 22079855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
    Mahaffey KW; Ferguson JJ
    Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated heparin among patients with ST-segment elevation myocardial infarction treated with thrombolysis. A meta-analysis of the randomized trials.
    De Luca G; Marino P
    Am Heart J; 2007 Dec; 154(6):1085.e1-6. PubMed ID: 18035079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis.
    Gabriel RS; White HD
    Expert Rev Cardiovasc Ther; 2007 Sep; 5(5):851-7. PubMed ID: 17867915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous enoxaparin following thrombolysis and intravenous unfractionated heparin in ST-elevation acute myocardial infarction: safety and efficacy of low vs full dose.
    Rubboli A; Gatti C; Spinolo L; Parollo R; Spitali G; Maresta A
    Minerva Cardioangiol; 2006 Feb; 54(1):131-7. PubMed ID: 16467747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective evaluation of clinical outcomes after acute ST-elevation myocardial infarction in patients who are ineligible for reperfusion therapy: preliminary results from the TETAMI registry and randomized trial.
    Cohen M; Gensini GF; Maritz F; Gurfinkel EP; Huber K; Timerman A; Krzeminska-Pakula M; Santopinto J; Hecquet C; Vittori L;
    Circulation; 2003 Oct; 108(16 Suppl 1):III14-21. PubMed ID: 14605015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.